{
  "source": "PA-Notification-Strensiq.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1176-10\nProgram Prior Authorization/Notification\nMedication Strensiq™ (asfotase alfa)\nP&T Approval Date 2/2016, 12/2016, 11/2017, 11/2018, 11/2019, 11/2020, 11/2021,\n11/2022, 11/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nStrensiq (asfotase alfa) is a tissue nonspecific alkaline phosphatase indicated for the treatment of\npatients with perinatal/infantile and juvenile-onset hypophosphatasia (HPP).\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Strensiq will be approved based on one of the following criteria:\na. Diagnosis of perinatal/infantile-onset hypophosphatasia\n-OR-\nb. Diagnosis of juvenile-onset hypophosphatasia\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Strensiq will be approved based on the following criterion:\na. Documentation of positive clinical response to Strensiq therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n© 2024 UnitedHealthcare Services, Inc.\n1\n4. References:\n1. Strensiq [package insert]. Boston, MA: Alexion Pharmaceuticals, Inc.; July 2024.\nProgram Prior Authorization/Notification - Strensiq (asfotase alfa)\nChange Control\n2/2016 New program.\n12/2016 Annual Review. Revised background. Extended initial authorization to\n12 months.\n11/2017 Annual Review. Updated references.\n11/2018 Annual Review. Updated references.\n11/2019 Annual Review. No changes.\n11/2020 Annual review. Updated reference",
    "ed initial authorization to\n12 months.\n11/2017 Annual Review. Updated references.\n11/2018 Annual Review. Updated references.\n11/2019 Annual Review. No changes.\n11/2020 Annual review. Updated reference.\n11/2021 Annual review with no changes to clinical coverage criteria.\n11/2022 Annual review with no changes to clinical coverage criteria. Added\nstate mandate footnote.\n11/2023 Annual review with no changes to clinical coverage criteria.\n10/2024 Annual review with no changes to clinical coverage criteria. Updated\nreference.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}